Orexo broadens ZUBSOLV® product range and announces newly listed granted US patent.

Uppsala, Sweden – February 17, 2015 – Orexo AB (publ) announces today that it
has initiated the launch of a new higher ZUBSOLV tablet strength (8.6 mg/2.1 mg
buprenorphine/naloxone CIII sublingual tablets). Furthermore, a new patent
covering ZUBSOLV was issued in the U.S. The patent is listed in the Orange Book
by U.S. Food and Drug Administration and expires in 2032.

In December two new dosage strengths of ZUBSOLV were approved by the U.S. Food
and Drug Administration (FDA). Orexo is now prepared to begin distribution and
commence the launch of the 8.6 mg dosage, after having received final clearance
of the REMS material. The updated REMS material is now published at
www.BTODREMS.com. The new 8.6 mg dosage complements the existing dosage range of
5.7 mg/1.4 mg and 1.4 mg/0.36 mg tablets enabling more patients to receive their
optimal dose in one tablet. The new ZUBSOLV dosage strength is based on the same
advanced, proprietary sublingual tablet formulation used for the already
launched ZUBSOLV tablets, providing higher bioavailability, fast dissolve time,
small tablet size, and menthol flavor. The new dosage is expected to be
available for patients in the first half of March.

In January the United States Patent and Trademark Office issued a new patent
protecting ZUBSOLV, U.S. Patent No. 8,940,330. The patent is the fourth patent
listed in the Orange Book by the FDA covering ZUBSOLV and expires on September
18, 2032.

“The continued development of the ZUBSOLV product range is a core element of
Orexo’s strategy. We invest significant resources in developing the product
through clinical research and pharmaceutical development to the benefit of
patients suffering from opioid dependence. A solid patent protection platform is
essential to enable these investments. With this latest patent, we gain
additional confidence and commitment to our continued efforts to improve the
treatment of opioid dependence.” said Nikolaj Sørensen, CEO and President of
Orexo AB.

For further information, please contact:
Nikolaj Sørensen, President and CEO
Tel: +46 (0)703-50 78 88, E-mail: ir@orexo.com

About Orexo AB
Orexo is a specialty pharma company with commercial operations in the United
States and R&D in Sweden developing improved treatments using proprietary drug
delivery. The company is commercializing its proprietary product, ZUBSOLV®
sublingual tablets, for maintenance treatment of opioid dependence, in the
United States. The ZUBSOLV sublingual tablet is a novel formulation of
buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual
technologies. Orexo has a portfolio of two approved and revenue generating
products currently marketed under license in the US, EU and Japan. Orexo AB,
with its headquarters in Sweden, is listed on Nasdaq Stockholm Exchange (STO:
ORX) and its American Depositary Receipts (ADRs) trade on the OTCQX marketplace
in the U.S. under the symbol, “ORXOY”. The largest shareholders are Novo A/S and
HealthCap.

For information about Orexo and ZUBSOLV, please visit www.orexo.com and
www.zubsolv.com.

Orexo AB (publ) discloses the information provided herein pursuant to the
Financial Instruments Trading Act and/or the Securities Markets Act. The
information was submitted for publication at 8:30am CET on February 17, 2015.